Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Recruiting

Early Phase 1

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent SarcomaImplantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT04199026

Conditions

Metastatic Sarcoma

Recurrent Sarcoma

Resectable Sarcoma

Eligibility Criteria

Sex: All

Age: 10+

Healthy Volunteers: Not accepted

Interventions

Doxorubicin

Doxorubicin Hydrochloride

Drug Delivery Microdevice

Everolimus

Ganitumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-25. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2025-02-28.